Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis

BACKGROUND: The primary objective was to demonstrate the safety and tolerability of monoclonal antibody against CD14 (IC14) (atibuclimab) in amyotrophic lateral sclerosis patients. The secondary objectives were pharmacokinetics, pharmacodynamics, and preliminary effects on disease status and biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Robert D., Agosti, Jan M., McCombe, Pamela A., Thorpe, Kathryn, Heggie, Susan, Heshmat, Saman, Appleby, Mark W., Ziegelaar, Brian W., Crowe, David T., Redlich, Garry L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542123/
https://www.ncbi.nlm.nih.gov/pubmed/34678870
http://dx.doi.org/10.1097/MD.0000000000027421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542123/
https://www.ncbi.nlm.nih.gov/pubmed/34678870
http://dx.doi.org/10.1097/MD.0000000000027421

Ejemplares similares